Hub : Traits :

Overall health rating

357 significantly associated models · 120 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 117211384 118766534 1 1 7.9e-11 1.1e-09 7.8e-01 100 MAN1A2
2 1 155424065 156838141 1 1 2.1e-07 3.8e-07 1.0e+00 100 SEMA4A
3 1 201164764 202607593 2 1 2.3e-10 1.9e-10 1.0e+00 100 LMOD1
4 1 242590540 244345666 3 1 2.9e-08 1.8e-09 4.6e-06 42 SDCCAG8
5 2 64586858 66006558 1 1 6.7e-08 1.3e-06 3.8e-01 97 CEP68
6 2 108372251 110002052 2 1 2.9e-08 2.4e-08 2.2e-01 95 GCC2
7 2 197745121 200117777 3 1 1.3e-09 1.4e-09 1.0e+00 100 MARS2
8 2 207107801 208729540 2 1 1.8e-08 3.8e-08 1.0e+00 100 CPO
9 3 48381826 51077419 26 1 3.5e-17 1.7e-14 5.5e-01 99 RNF123
10 3 135861666 137253713 1 1 2.4e-07 2.5e-06 1.6e-01 91 RP11-731C17.2
11 4 1586036 3943984 8 2 3.3e-14 3.3e-13 1.0e+00 100 GRK4 RNF4
12 4 89947254 91439574 1 1 1.4e-07 5.1e-08 2.1e-02 82 SNCA
13 4 158997448 160525502 1 1 3.7e-08 3.7e-09 1.0e+00 100 FNIP2
14 5 138036255 139419985 1 1 3.5e-07 5.1e-07 2.4e-01 95 PROB1
15 6 33857525 35542476 2 2 1.3e-07 1.9e-08 3.0e-01 97 C6orf106 UHRF1BP1
16 7 1161158 2972072 1 1 2.7e-07 8.4e-12 4.3e-07 45 MAD1L1
17 7 73624615 74494207 1 1 4.0e-07 9.3e-07 1.0e+00 100 PMS2P5
18 8 8165004 10985432 3 2 7.7e-09 3.5e-10 2.6e-03 77 MSRA RP11-375N15.2
19 8 11276542 13120332 1 1 2.2e-07 1.2e-08 4.4e-03 75 LOC100506990
20 8 29996824 31433801 1 1 8.1e-12 7.2e-12 4.0e-03 82 TEX15
21 8 142629143 144179460 1 1 1.7e-10 1.1e-06 3.1e-01 96 TSNARE1
22 9 13891813 15288045 1 1 1.7e-07 2.0e-07 6.5e-02 87 RP11-408A13.4
23 9 95502571 96910958 2 2 2.0e-07 3.6e-08 4.1e-02 86 FAM120AOS RP11-165J3.6
24 9 126927285 129422783 5 2 2.3e-10 1.2e-12 2.3e-02 90 PBX3 PPP6C
25 10 98926838 100488720 1 1 1.7e-08 4.9e-07 6.9e-02 87 CRTAC1
26 11 64501991 67059499 12 3 1.1e-10 1.0e-07 6.2e-02 88 CTD-3074O7.5 NEAT1 SIPA1
27 11 76827992 78216992 1 1 9.7e-08 3.3e-06 4.6e-01 97 AP000580.1
28 11 112486568 113952419 2 1 2.0e-09 5.6e-09 2.0e-01 95 TTC12
29 12 55746910 57125879 1 1 2.8e-07 7.8e-06 2.6e-02 75 RPS26
30 13 31078511 32595740 1 1 2.3e-07 2.6e-08 3.2e-02 85 B3GALTL
31 14 69027866 70518587 1 1 1.6e-08 3.4e-09 2.8e-03 74 GALNT16
32 14 76886528 78423788 1 1 4.0e-07 1.3e-07 3.3e-02 84 TMEM63C
33 15 73524629 74968873 2 2 1.9e-08 3.8e-06 3.6e-02 80 LOXL1-AS1 STOML1
34 16 29972690 31892919 10 1 3.5e-10 7.9e-11 2.5e-02 88 KAT8
35 16 52772129 54210447 1 1 2.6e-07 2.7e-07 1.2e-05 27 RBL2
36 16 71070698 72569466 3 1 3.0e-08 8.7e-08 5.5e-01 99 PHLPP2
37 17 1594359 3000009 2 1 1.2e-07 2.5e-07 5.4e-01 99 RP1-59D14.1
38 17 65289798 66851185 5 2 7.6e-09 7.7e-09 2.3e-01 96 LINC00674 LOC651250
39 19 1226004 2732986 2 1 2.0e-08 3.6e-09 1.3e-02 82 BTBD2
40 19 18359524 19753882 1 1 2.9e-07 1.1e-05 9.1e-06 -2 AC005932.1
41 20 2390880 3830474 1 1 4.0e-07 1.7e-06 1.9e-01 92 UBOX5

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Alzheimer’s Disease (in mother) 1.34 1 0 0.0 0.00 1.0e+00 KAT8
Alzheimer’s Disease (including proxy) 1.18 1 1 3.0 0.00 1.0e+00 KAT8
Crohns Disease (2017) 1.32 3 1 3.0 0.00 1.0e+00 MARS2 PMS2P5 RNF123
Irritable Bowel Disease (IBD) 1.33 2 1 3.0 0.00 1.0e+00 PMS2P5 RNF123
Ulcerative Colitis (UC) 1.29 1 1 3.0 0.00 1.0e+00 RNF123
Major Depression (MDD) 2.98 2 0 0.0 0.00 1.0e+00 CPO FAM120AOS
Reaction Time 1.14 1 0 0.0 0.00 1.0e+00 SDCCAG8
Verbal and Numeric Reasoning (VNR) 2.85 6 3 9.1 0.97 1.1e-03 FAM120AOS PHLPP2 RBL2 RNF123 RP11-731C17.2 TEX15
Breast Cancer 1.65 4 1 3.0 0.98 1.6e-02 CTD-3074O7.5 PMS2P5 SEMA4A SIPA1
Prostate Cancer 1.31 1 0 0.0 0.00 1.0e+00 RNF123
Age at First Birth 2.96 1 1 3.0 0.00 1.0e+00 RNF123
Body Mass Index (BMI) (2010) 2.05 2 0 0.0 0.00 1.0e+00 LMOD1 UHRF1BP1
Coronary Artery Disease (CAD) 1.87 1 0 0.0 0.00 1.0e+00 LMOD1
Crohns Disease (2012) 1.59 2 0 0.0 0.00 1.0e+00 MARS2 RNF123
HDL Cholesterol 2.31 4 2 6.1 -0.53 4.7e-01 C6orf106 CEP68 SIPA1 UHRF1BP1
LDL Cholesterol 1.54 1 1 3.0 0.00 1.0e+00 C6orf106
Neuroticism 2.91 4 1 3.0 0.54 4.6e-01 CPO LOC100506990 MSRA RP1-59D14.1
Rheumatoid Arthritis 1.56 1 0 0.0 0.00 1.0e+00 RPS26
Schizophrenia 1.86 3 1 3.0 0.00 1.0e+00 MARS2 SDCCAG8 TSNARE1
Triglycerides 2.05 2 1 3.0 0.00 1.0e+00 KAT8 LOC100506990
Ulcerative Colitis 1.26 1 0 0.0 0.00 1.0e+00 RNF123
Blood Eosinophil Count 1.17 6 3 9.1 -0.30 5.7e-01 LINC00674 LOC651250 NEAT1 PHLPP2 RNF123 RPS26
Blood Platelet Count 1.35 12 7 21.2 -0.02 9.6e-01 AP000580.1 C6orf106 FAM120AOS GCC2 GRK4 LOC651250 MARS2 NEAT1 RP1-59D14.1 SEMA4A SIPA1 UHRF1BP1
Blood Red Count 0.74 8 5 15.2 -0.17 6.9e-01 C6orf106 CTD-3074O7.5 KAT8 MARS2 RP1-59D14.1 RPS26 SEMA4A SIPA1
Blood White Count 0.95 6 3 9.1 -0.66 1.5e-01 GRK4 KAT8 RNF123 TEX15 UBOX5 UHRF1BP1
Heel T-Score 1.11 9 4 12.1 0.15 7.1e-01 AP000580.1 B3GALTL CTD-3074O7.5 FAM120AOS KAT8 LINC00674 PMS2P5 RP11-375N15.2 SIPA1
BMI 4.69 24 18 54.5 -0.92 2.5e-10 BTBD2 C6orf106 CRTAC1 CTD-3074O7.5 FNIP2 GALNT16 GRK4 KAT8 LINC00674 LMOD1 LOC651250 MAN1A2 MARS2 NEAT1 PMS2P5 RNF123 RP11-408A13.4 RP11-731C17.2 RPS26 SIPA1 STOML1 TEX15 TTC12 UHRF1BP1
Height 2.01 16 13 39.4 0.24 3.8e-01 AP000580.1 C6orf106 GCC2 LINC00674 LOXL1-AS1 NEAT1 PBX3 PHLPP2 PROB1 RBL2 RP11-165J3.6 RP11-731C17.2 SIPA1 STOML1 UBOX5 UHRF1BP1
Waist Hip Ratio (WHR) 1.41 8 1 3.0 -0.37 3.7e-01 C6orf106 LOC651250 MARS2 PBX3 RBL2 SIPA1 TTC12 UHRF1BP1
Systolic Blood Pressure 1.63 9 5 15.2 -0.13 7.4e-01 CEP68 LINC00674 PBX3 PHLPP2 PMS2P5 PROB1 RNF123 SIPA1 TSNARE1
Smoking Status 2.44 6 1 3.0 -0.97 1.8e-03 GRK4 KAT8 MAD1L1 PBX3 PPP6C RNF123
Allergy or Eczema 1.89 4 2 6.1 0.61 3.9e-01 AP000580.1 C6orf106 MARS2 RPS26
Cardiovascular Disease 2.97 13 4 12.1 -0.94 2.1e-06 CEP68 GRK4 KAT8 LMOD1 MAD1L1 PMS2P5 RPS26 SDCCAG8 SIPA1 TEX15 TSNARE1 TTC12 UHRF1BP1
Respiratory disease 1.45 1 0 0.0 0.00 1.0e+00 RNF123
Type 2 Diabetes (T2D) 2.81 8 3 9.1 -0.96 1.3e-04 KAT8 LINC00674 LOC651250 NEAT1 PMS2P5 RBL2 RNF123 SIPA1
Lung FEV1/FVC ratio 1.42 5 3 9.1 -0.72 1.7e-01 C6orf106 FAM120AOS LINC00674 LMOD1 LOXL1-AS1
Lung FVC 1.29 8 4 12.1 0.61 1.1e-01 C6orf106 CTD-3074O7.5 GRK4 KAT8 LINC00674 PPP6C RNF123 UHRF1BP1
Neuroticism 3.33 9 3 9.1 -0.75 1.9e-02 FAM120AOS GALNT16 KAT8 RNF123 RP11-165J3.6 RP1-59D14.1 SDCCAG8 TSNARE1 TTC12
Chronotype (morning person) 1.50 2 1 3.0 0.00 1.0e+00 LMOD1 MARS2
Hair Pigment 0.11 3 1 3.0 0.00 1.0e+00 C6orf106 LINC00674 SIPA1
Hand grip strength (left) 1.81 3 2 6.1 0.00 1.0e+00 AP000580.1 C6orf106 LOXL1-AS1
Number of treatments/medications taken 4.21 4 1 3.0 1.00 2.8e-03 LINC00674 PMS2P5 PPP6C RNF123
Sensitivity / hurt feelings 2.41 3 1 3.0 0.00 1.0e+00 PBX3 RP11-165J3.6 TTC12
Frequency of depressed mood in last 2 weeks 3.28 3 1 3.0 0.00 1.0e+00 CPO FAM120AOS RP11-165J3.6
Hearing difficulty/problems: Yes 1.96 2 0 0.0 0.00 1.0e+00 CPO FAM120AOS
Relative age of first facial hair 1.50 1 1 3.0 0.00 1.0e+00 C6orf106
Other serious medical condition/disability diagnosed by doctor 2.70 1 0 0.0 0.00 1.0e+00 TTC12
Systolic blood pressure, automated reading 2.09 7 3 9.1 0.96 5.3e-04 CEP68 LOC100506990 MSRA PMS2P5 RNF123 SIPA1 TSNARE1
Angina 2.08 1 0 0.0 0.00 1.0e+00 CPO
Medication: Co-codamol 2.83 1 0 0.0 0.00 1.0e+00 RNF123
Medication: Metformin 3.17 2 0 0.0 0.00 1.0e+00 LOC651250 PMS2P5
Pack years adult smoking proportion 2.44 3 0 0.0 0.00 1.0e+00 GRK4 PMS2P5 RP1-59D14.1
Impedance of leg (right) 2.69 13 8 24.2 -0.73 4.8e-03 C6orf106 CPO KAT8 LMOD1 LOC100506990 MARS2 MSRA NEAT1 PMS2P5 RNF123 RP11-731C17.2 RP1-59D14.1 UHRF1BP1
Leg fat-free mass (left) 3.55 15 7 21.2 0.65 9.0e-03 BTBD2 C6orf106 CPO KAT8 LINC00674 LMOD1 LOC100506990 MARS2 MSRA NEAT1 PHLPP2 RBL2 RNF123 RP11-408A13.4 UHRF1BP1
Trunk fat percentage 4.35 16 10 30.3 0.92 3.0e-07 AC005932.1 C6orf106 CRTAC1 CTD-3074O7.5 GALNT16 GRK4 KAT8 LINC00674 LMOD1 LOC651250 MAD1L1 RNF123 RP1-59D14.1 TEX15 TTC12 UHRF1BP1
Hand grip strength (right) 1.98 4 2 6.1 -0.65 3.5e-01 AP000580.1 C6orf106 LOXL1-AS1 PPP6C
Current tobacco smoking 3.09 4 0 0.0 1.00 1.1e-03 FNIP2 MSRA PBX3 PPP6C
Fed-up feelings 3.51 6 1 3.0 0.99 6.3e-05 GALNT16 LINC00674 LOC651250 RNF123 TEX15 TTC12
Frequency of unenthusiasm / disinterest in last 2 weeks 4.70 4 1 3.0 -0.17 8.3e-01 GALNT16 PHLPP2 RP11-165J3.6 TTC12
Relative age voice broke 1.68 1 0 0.0 0.00 1.0e+00 PMS2P5
Taking other prescription medications 3.45 3 1 3.0 0.00 1.0e+00 LINC00674 PMS2P5 RNF123
Age when periods started (menarche) 2.34 5 2 6.1 -0.54 3.5e-01 PMS2P5 RNF123 RNF4 RPS26 SIPA1
Heel bone mineral density (BMD) T-score, automated (left) 1.85 3 2 6.1 0.00 1.0e+00 LOC100506990 MSRA SIPA1
Qualifications: CSEs or equivalent 1.93 2 0 0.0 0.00 1.0e+00 FNIP2 RNF123
High blood pressure 3.51 13 5 15.2 0.96 1.1e-07 CEP68 KAT8 LMOD1 LOC100506990 MSRA PMS2P5 RBL2 RP11-375N15.2 RPS26 SDCCAG8 SIPA1 TEX15 TSNARE1
Hayfever, allergic rhinitis or eczema 1.78 3 1 3.0 0.00 1.0e+00 C6orf106 MARS2 RPS26
Stomach or abdominal pain in last month 2.57 1 0 0.0 0.00 1.0e+00 RP11-165J3.6
Medication: Levothyroxine sodium 1.35 2 0 0.0 0.00 1.0e+00 MSRA UHRF1BP1
Sitting height 1.32 5 4 12.1 -0.15 8.1e-01 C6orf106 LOXL1-AS1 PROB1 RBL2 UHRF1BP1
Body mass index (BMI) 6.00 25 19 57.6 0.95 1.2e-12 BTBD2 C6orf106 CRTAC1 CTD-3074O7.5 FNIP2 GALNT16 GRK4 KAT8 LINC00674 LMOD1 LOC100506990 LOC651250 MARS2 MSRA NEAT1 PMS2P5 RNF123 RP11-375N15.2 RP11-408A13.4 RP11-731C17.2 SIPA1 SNCA STOML1 TEX15 UHRF1BP1
Impedance of leg (left) 2.64 15 8 24.2 -0.78 6.7e-04 BTBD2 C6orf106 CPO CRTAC1 KAT8 LMOD1 LOC100506990 MARS2 MSRA NEAT1 PMS2P5 RNF123 RP11-731C17.2 RP1-59D14.1 UHRF1BP1
Leg predicted mass (left) 3.51 15 7 21.2 0.65 8.8e-03 BTBD2 C6orf106 CPO KAT8 LINC00674 LMOD1 LOC100506990 MARS2 MSRA NEAT1 PHLPP2 RBL2 RNF123 RP11-408A13.4 UHRF1BP1
Trunk fat mass 4.97 18 10 30.3 0.89 8.9e-07 AC005932.1 BTBD2 C6orf106 CRTAC1 CTD-3074O7.5 GALNT16 GRK4 KAT8 LINC00674 LMOD1 LOC651250 MAD1L1 MSRA NEAT1 RNF123 TEX15 TTC12 UHRF1BP1
Waist circumference 5.16 18 11 33.3 0.93 1.4e-08 AC005932.1 BTBD2 C6orf106 CRTAC1 CTD-3074O7.5 GRK4 KAT8 LINC00674 LMOD1 LOC651250 NEAT1 PMS2P5 RNF123 RP11-408A13.4 SIPA1 TEX15 TTC12 UHRF1BP1
Number of incorrect matches in round 1.52 1 1 3.0 0.00 1.0e+00 KAT8
Alcohol usually taken with meals 3.13 3 1 3.0 0.00 1.0e+00 LMOD1 RP1-59D14.1 TSNARE1
Nervous feelings 2.99 4 1 3.0 -0.55 4.5e-01 KAT8 LOC100506990 MSRA TSNARE1
Frequency of tenseness / restlessness in last 2 weeks 3.04 4 0 0.0 0.99 1.2e-02 B3GALTL CPO RNF123 RP11-165J3.6
Hearing difficulty/problems with background noise 1.74 1 0 0.0 0.00 1.0e+00 CPO
Hair/balding pattern: Pattern 2 1.06 1 0 0.0 0.00 1.0e+00 PROB1
Forced vital capacity (FVC) 1.85 9 3 9.1 -0.69 4.1e-02 AP000580.1 C6orf106 CTD-3074O7.5 GRK4 KAT8 LOC100506990 LOXL1-AS1 PPP6C RNF123
Heel bone mineral density (BMD) T-score, automated (right) 1.76 3 2 6.1 0.00 1.0e+00 LOC100506990 MSRA SIPA1
Ever unenthusiastic/disinterested for a whole week 1.85 1 0 0.0 0.00 1.0e+00 RNF123
Qualifications: None of the above 3.93 10 4 12.1 0.99 5.8e-08 B3GALTL FAM120AOS GALNT16 GRK4 PHLPP2 RNF123 RPS26 SDCCAG8 TEX15 TSNARE1
Financial difficulties in last 2 years 3.10 2 0 0.0 0.00 1.0e+00 KAT8 PBX3
Mouth/teeth dental problems 3.19 3 0 0.0 0.00 1.0e+00 PMS2P5 SDCCAG8 SIPA1
Allergy 1.75 4 1 3.0 0.57 4.3e-01 AP000580.1 C6orf106 MARS2 RPS26
Pain all over the body in last month 2.62 1 0 0.0 0.00 1.0e+00 RNF123
Diabetes (self-reported) 2.83 3 1 3.0 0.00 1.0e+00 PMS2P5 RBL2 RNF123
Hayfever/allergic rhinitis (self-reported) 1.48 1 0 0.0 0.00 1.0e+00 MARS2
Medication: Simvastatin 1.74 1 0 0.0 0.00 1.0e+00 SIPA1
Fluid intelligence score 2.58 5 1 3.0 -0.97 5.0e-03 LMOD1 PHLPP2 RBL2 RNF123 TEX15
Illnesses of siblings 2.59 1 0 0.0 0.00 1.0e+00 KAT8
Neuroticism score 3.79 8 5 15.2 0.41 3.1e-01 FAM120AOS GALNT16 LOC100506990 MSRA RNF123 RP11-165J3.6 RP1-59D14.1 TTC12
Weight 5.03 17 10 30.3 0.86 8.1e-06 BTBD2 C6orf106 CRTAC1 CTD-3074O7.5 KAT8 LINC00674 LMOD1 LOC100506990 LOC651250 MARS2 MSRA NEAT1 PHLPP2 RNF123 RP11-408A13.4 TEX15 UHRF1BP1
Impedance of arm (right) 3.44 16 8 24.2 -0.96 5.7e-09 C6orf106 CRTAC1 FAM120AOS FNIP2 KAT8 LMOD1 LOC100506990 MARS2 MSRA NEAT1 RNF123 RP11-408A13.4 RP11-731C17.2 RPS26 STOML1 UHRF1BP1
Arm fat percentage (right) 4.78 21 12 36.4 0.96 1.5e-11 AC005932.1 BTBD2 C6orf106 CRTAC1 CTD-3074O7.5 GALNT16 GRK4 KAT8 LINC00674 LMOD1 LOC100506990 LOC651250 MAD1L1 MSRA NEAT1 PMS2P5 RNF123 SIPA1 TEX15 TTC12 UHRF1BP1
Trunk fat-free mass 2.97 11 8 24.2 0.52 9.8e-02 C6orf106 CPO FNIP2 KAT8 LMOD1 LOXL1-AS1 MARS2 PHLPP2 PROB1 RNF123 UHRF1BP1
Hip circumference 4.62 14 7 21.2 0.87 4.5e-05 BTBD2 C6orf106 CRTAC1 CTD-3074O7.5 KAT8 LINC00674 LMOD1 LOC100506990 LOC651250 MSRA PMS2P5 RNF123 TEX15 UHRF1BP1
Alcohol intake versus 10 years previously 1.45 1 0 0.0 0.00 1.0e+00 RNF123
Father's age at death 2.31 1 0 0.0 0.00 1.0e+00 LOC100506990
Worrier / anxious feelings 2.78 5 2 6.1 -0.12 8.4e-01 B3GALTL LOC100506990 MSRA RP11-165J3.6 RP11-731C17.2
Frequency of tiredness / lethargy in last 2 weeks 6.24 12 3 9.1 0.99 1.2e-09 CPO GALNT16 LMOD1 LOC651250 PHLPP2 RNF4 RP11-165J3.6 RP11-731C17.2 RP1-59D14.1 STOML1 TTC12 UBOX5
Number of live births 1.93 2 0 0.0 0.00 1.0e+00 MAN1A2 RP11-408A13.4
Forced expiratory volume in 1-second (FEV1) 2.16 9 5 15.2 -0.65 5.9e-02 AP000580.1 C6orf106 CTD-3074O7.5 GRK4 KAT8 LOC100506990 MSRA PPP6C RNF123
Pulse rate 1.56 2 0 0.0 0.00 1.0e+00 FNIP2 RBL2
Qualifications: A levels/AS levels or equivalent 3.52 7 2 6.1 -0.95 8.6e-04 FAM120AOS GRK4 RNF123 SDCCAG8 TEX15 TSNARE1 UBOX5
Mouth/teeth dental problems: Dentures 3.04 3 0 0.0 0.00 1.0e+00 PMS2P5 RNF123 RP11-731C17.2
Medication: Cholesterol lowering 1.83 2 0 0.0 0.00 1.0e+00 KAT8 SIPA1
Medication: Lansoprazole 1.97 1 0 0.0 0.00 1.0e+00 GALNT16
Forced expiratory volume in 1-second (FEV1), Best measure 1.93 8 2 6.1 -0.54 1.6e-01 AP000580.1 C6orf106 GRK4 KAT8 LOC100506990 MSRA RNF123 SDCCAG8
Impedance of arm (left) 3.40 14 9 27.3 -0.95 1.3e-07 C6orf106 FNIP2 KAT8 LMOD1 LOC100506990 MARS2 MSRA NEAT1 RNF123 RP11-408A13.4 RP11-731C17.2 RPS26 STOML1 UHRF1BP1
Arm fat mass (right) 5.54 20 13 39.4 0.92 9.4e-09 BTBD2 C6orf106 CRTAC1 CTD-3074O7.5 GALNT16 GRK4 KAT8 LINC00674 LMOD1 LOC100506990 LOC651250 MSRA NEAT1 PMS2P5 RNF123 RP11-408A13.4 SIPA1 TEX15 TTC12 UHRF1BP1
Trunk predicted mass 2.97 11 8 24.2 0.52 9.7e-02 C6orf106 CPO FNIP2 KAT8 LMOD1 LOXL1-AS1 MARS2 PHLPP2 PROB1 RNF123 UHRF1BP1
Standing height 2.22 16 11 33.3 -0.35 1.8e-01 AP000580.1 C6orf106 GRK4 LINC00674 LOC100506990 LOXL1-AS1 MSRA PBX3 PHLPP2 PROB1 RBL2 RP11-165J3.6 RP11-731C17.2 SIPA1 STOML1 UHRF1BP1
Exposure to tobacco smoke at home 2.14 1 1 3.0 0.00 1.0e+00 RNF123
Tense / 'highly strung' 2.53 3 1 3.0 0.00 1.0e+00 KAT8 LOC100506990 RP11-165J3.6
Seen doctor (GP) for nerves, anxiety, tension or depression 2.72 2 0 0.0 0.00 1.0e+00 B3GALTL CTD-3074O7.5
Peak expiratory flow (PEF) 1.85 6 2 6.1 -0.68 1.4e-01 AP000580.1 C6orf106 LOC100506990 MSRA PPP6C RP11-375N15.2
Ever highly irritable/argumentative for 2 days 2.09 1 0 0.0 0.00 1.0e+00 RNF123
Qualifications: O levels/GCSEs or equivalent 2.45 3 0 0.0 0.00 1.0e+00 GRK4 RNF123 TSNARE1
Medication: Paracetamol 2.62 3 1 3.0 0.00 1.0e+00 CPO RNF123 SDCCAG8
Headache pain in last month 2.26 1 1 3.0 0.00 1.0e+00 SDCCAG8
Medication for cholesterol, blood pressure or diabetes 2.08 1 0 0.0 0.00 1.0e+00 SIPA1
Hypothyroidism/myxoedema (self-reported) 1.40 1 0 0.0 0.00 1.0e+00 MSRA
Medication: Amlodipine 1.61 1 0 0.0 0.00 1.0e+00 SDCCAG8
Birth weight 1.79 2 1 3.0 0.00 1.0e+00 GCC2 NEAT1
Chronic bronchitis/emphysema (mother) 1.48 1 0 0.0 0.00 1.0e+00 RNF123
High blood pressure (siblings) 2.12 1 0 0.0 0.00 1.0e+00 KAT8
Forced vital capacity (FVC), Best measure 1.65 6 1 3.0 -0.69 1.3e-01 AP000580.1 C6orf106 GRK4 KAT8 LOXL1-AS1 RNF123
Body fat percentage 4.91 21 11 33.3 0.95 9.4e-11 AC005932.1 BTBD2 C6orf106 CRTAC1 CTD-3074O7.5 GALNT16 GRK4 KAT8 LINC00674 LMOD1 LOC651250 MAD1L1 MSRA NEAT1 PMS2P5 RNF123 RP1-59D14.1 SIPA1 TEX15 TTC12 UHRF1BP1
Leg fat percentage (right) 5.33 19 12 36.4 0.96 1.1e-10 C6orf106 CRTAC1 CTD-3074O7.5 GALNT16 GRK4 KAT8 LINC00674 LMOD1 LOC651250 MSRA NEAT1 PMS2P5 RBL2 RNF123 RP1-59D14.1 SNCA TEX15 TTC12 UHRF1BP1
Arm fat-free mass (right) 3.72 12 7 21.2 0.52 8.2e-02 C6orf106 CPO KAT8 LMOD1 LOC100506990 MARS2 NEAT1 PHLPP2 PROB1 RNF123 RP11-408A13.4 UHRF1BP1
Exposure to tobacco smoke outside home 3.10 4 0 0.0 0.99 8.9e-03 FNIP2 MARS2 RNF123 SDCCAG8
Comparative body size at age 10 2.18 8 2 6.1 0.41 3.1e-01 FAM120AOS LMOD1 LOC100506990 MARS2 MSRA NEAT1 RP11-165J3.6 UHRF1BP1
Worry too long after embarrassment 2.17 4 2 6.1 0.11 8.9e-01 LOC100506990 MSRA RP1-59D14.1 TTC12
Wheeze or whistling in the chest in last year 3.79 4 1 3.0 0.99 5.2e-03 KAT8 LINC00674 LMOD1 RNF123
Reason for reducing amount of alcohol drunk: Health precaution 1.67 1 0 0.0 0.00 1.0e+00 RPS26
Age at first live birth 4.64 6 1 3.0 -0.99 9.0e-05 LMOD1 PHLPP2 RNF123 RNF4 RP11-408A13.4 STOML1
Health satisfaction 6.22 7 1 3.0 0.99 1.7e-05 CTD-3074O7.5 GRK4 LINC00674 LMOD1 LOC651250 RNF123 TSNARE1
Shortness of breath walking on level ground 3.14 2 0 0.0 0.00 1.0e+00 LMOD1 PHLPP2
Qualifications: College or University degree 4.29 14 7 21.2 -0.97 3.7e-09 B3GALTL FAM120AOS FNIP2 GALNT16 GRK4 LMOD1 NEAT1 RBL2 RNF123 RP1-59D14.1 SDCCAG8 TEX15 TSNARE1 UBOX5
Emphysema/chronic bronchitis 1.96 1 0 0.0 0.00 1.0e+00 RP11-375N15.2
Medication for pain relief, constipation, heartburn 3.83 6 1 3.0 -0.99 1.7e-04 CPO LMOD1 RP11-165J3.6 SDCCAG8 TEX15 UHRF1BP1
Neck or shoulder pain in last month 3.23 1 0 0.0 0.00 1.0e+00 PHLPP2
Medication: Blood pressure 2.08 2 0 0.0 0.00 1.0e+00 MSRA SIPA1
Medication: Omeprazole 2.28 2 0 0.0 0.00 1.0e+00 C6orf106 UHRF1BP1
Medication: Seretide 50 evohaler 1.47 1 0 0.0 0.00 1.0e+00 RNF123
Whole body fat mass 5.46 21 11 33.3 0.91 1.1e-08 AC005932.1 BTBD2 C6orf106 CRTAC1 CTD-3074O7.5 GALNT16 GRK4 KAT8 LINC00674 LMOD1 LOC100506990 LOC651250 MSRA NEAT1 PMS2P5 RNF123 RP11-408A13.4 SIPA1 TEX15 TTC12 UHRF1BP1
Leg fat mass (right) 6.05 20 13 39.4 0.92 1.1e-08 BTBD2 C6orf106 CRTAC1 CTD-3074O7.5 GALNT16 GRK4 KAT8 LINC00674 LMOD1 LOC100506990 LOC651250 MSRA NEAT1 PMS2P5 RNF123 RP11-408A13.4 SNCA TEX15 TTC12 UHRF1BP1
Arm predicted mass (right) 3.80 15 7 21.2 0.65 8.2e-03 C6orf106 CPO KAT8 LINC00674 LMOD1 LOC100506990 LOC651250 MARS2 MSRA NEAT1 PHLPP2 PROB1 RNF123 RP11-408A13.4 UHRF1BP1
Pulse rate, automated reading 2.25 7 5 15.2 0.11 8.2e-01 C6orf106 FNIP2 LMOD1 PROB1 RBL2 RP1-59D14.1 UHRF1BP1
Alcohol intake frequency. 3.06 9 2 6.1 0.97 1.6e-05 CRTAC1 CTD-3074O7.5 GALNT16 KAT8 PMS2P5 RNF123 RNF4 TEX15 TSNARE1
Comparative height size at age 10 1.59 11 3 9.1 -0.22 5.1e-01 C6orf106 LINC00674 LOXL1-AS1 PBX3 PHLPP2 PROB1 RBL2 RP11-731C17.2 STOML1 TTC12 UHRF1BP1
Suffer from 'nerves' 1.79 2 0 0.0 0.00 1.0e+00 LOC100506990 TTC12
Chest pain or discomfort 3.18 3 0 0.0 0.00 1.0e+00 CPO GRK4 MAN1A2
Age at last live birth 3.47 2 1 3.0 0.00 1.0e+00 LINC00674 RNF123
Leg pain on walking 3.04 1 0 0.0 0.00 1.0e+00 RNF123
Medication: Aspirin 2.24 2 0 0.0 0.00 1.0e+00 CPO LMOD1
Knee pain experienced in last month 3.09 3 0 0.0 0.00 1.0e+00 KAT8 PHLPP2 SDCCAG8
Hypertension (Self-reported) 3.45 13 5 15.2 0.97 5.6e-08 CEP68 KAT8 LMOD1 LOC100506990 MSRA PMS2P5 RBL2 RP11-375N15.2 RPS26 SDCCAG8 SIPA1 TEX15 TSNARE1
Illnesses of siblings: Diabetes 1.99 1 0 0.0 0.00 1.0e+00 PMS2P5
Smoking status: Previous 1.47 1 0 0.0 0.00 1.0e+00 SIPA1
Forced expiratory volume in 1-second (FEV1), predicted 1.68 1 1 3.0 0.00 1.0e+00 C6orf106
Whole body fat-free mass 3.30 12 7 21.2 0.58 4.9e-02 C6orf106 CPO KAT8 LMOD1 LOC100506990 MARS2 MSRA NEAT1 PHLPP2 PROB1 RNF123 UHRF1BP1
Leg fat-free mass (right) 3.38 13 6 18.2 0.63 2.0e-02 BTBD2 C6orf106 CPO KAT8 LMOD1 LOC100506990 MARS2 MSRA NEAT1 PHLPP2 RBL2 RNF123 UHRF1BP1
Arm fat percentage (left) 4.86 20 13 39.4 0.95 7.0e-11 AC005932.1 BTBD2 C6orf106 CRTAC1 CTD-3074O7.5 GRK4 KAT8 LINC00674 LMOD1 LOC100506990 LOC651250 MAD1L1 MSRA NEAT1 PMS2P5 RNF123 SIPA1 TEX15 TTC12 UHRF1BP1
Average weekly red wine intake 2.50 3 0 0.0 0.00 1.0e+00 CTD-3074O7.5 FNIP2 RP1-59D14.1
Mood swings 3.70 6 1 3.0 0.99 1.1e-04 AP000580.1 FAM120AOS GALNT16 RNF123 RP11-165J3.6 TTC12
Loneliness, isolation 3.44 3 1 3.0 0.00 1.0e+00 FAM120AOS LINC00674 RP11-165J3.6
Long-standing illness, disability or infirmity 4.76 5 0 0.0 1.00 7.3e-05 CTD-3074O7.5 PBX3 PMS2P5 TTC12 UBOX5
Diabetes diagnosed by doctor 2.91 2 1 3.0 0.00 1.0e+00 PMS2P5 RBL2
Qualifications: nursing, teaching 2.65 3 1 3.0 0.00 1.0e+00 GALNT16 LMOD1 RNF123
Back pain experienced in last month 3.43 3 0 0.0 0.00 1.0e+00 C6orf106 FNIP2 RPS26
Mineral and other dietary supplements 1.77 1 0 0.0 0.00 1.0e+00 GRK4
Osteoarthritis (self-reported) 2.46 2 0 0.0 0.00 1.0e+00 PBX3 RP11-165J3.6
Medication: Aspirin 2.24 1 0 0.0 0.00 1.0e+00 LMOD1
Smoking status: Current 2.97 4 0 0.0 1.00 2.1e-03 FNIP2 MSRA PBX3 PPP6C
Forced expiratory volume in 1-second (FEV1), predicted percentage 1.84 3 1 3.0 0.00 1.0e+00 GRK4 KAT8 RNF123
Whole body water mass 3.31 12 7 21.2 0.58 4.8e-02 C6orf106 CPO KAT8 LMOD1 LOC100506990 MARS2 MSRA NEAT1 PHLPP2 PROB1 RNF123 UHRF1BP1
Leg predicted mass (right) 3.36 13 6 18.2 0.63 2.0e-02 BTBD2 C6orf106 CPO KAT8 LMOD1 LOC100506990 MARS2 MSRA NEAT1 PHLPP2 RBL2 RNF123 UHRF1BP1
Arm fat mass (left) 5.60 19 13 39.4 0.92 3.2e-08 BTBD2 C6orf106 CRTAC1 CTD-3074O7.5 GRK4 KAT8 LINC00674 LMOD1 LOC100506990 LOC651250 MSRA NEAT1 PMS2P5 RNF123 RP11-408A13.4 SIPA1 TEX15 TTC12 UHRF1BP1
Number of self-reported non-cancer illnesses 3.79 5 1 3.0 0.96 8.7e-03 CEP68 MAN1A2 PMS2P5 PPP6C RNF123
Average weekly champagne plus white wine intake 2.06 1 0 0.0 0.00 1.0e+00 SIPA1
Miserableness 3.42 6 2 6.1 0.66 1.5e-01 B3GALTL LOC100506990 RNF123 RP11-165J3.6 SDCCAG8 TTC12
Guilty feelings 2.58 4 1 3.0 -0.09 9.1e-01 LOC100506990 MSRA RNF123 TTC12
Financial situation satisfaction 3.09 2 0 0.0 0.00 1.0e+00 PROB1 RNF123
Eye problems/disorders: Glaucoma 1.63 1 0 0.0 0.00 1.0e+00 TEX15
Medication: Blood pressure 2.73 4 1 3.0 0.98 2.4e-02 KAT8 LOC100506990 MSRA SIPA1
Pain type(s) experienced in last month: Hip pain 2.96 1 0 0.0 0.00 1.0e+00 CRTAC1
Supplements: Fish oil (including cod liver oil) 2.17 1 0 0.0 0.00 1.0e+00 GRK4
High cholesterol (Self-reported) 1.57 1 0 0.0 0.00 1.0e+00 RP11-375N15.2
Medication: Bendroflumethiazide 2.25 2 2 6.1 0.00 1.0e+00 LOC100506990 TEX15
Medication: Paracetamol 2.23 2 0 0.0 0.00 1.0e+00 RNF123 SDCCAG8
Basal metabolic rate 3.76 16 7 21.2 0.68 3.6e-03 BTBD2 C6orf106 CPO KAT8 LINC00674 LMOD1 LOC100506990 LOC651250 MARS2 MSRA NEAT1 PHLPP2 PROB1 RNF123 RP11-408A13.4 UHRF1BP1
Leg fat percentage (left) 5.47 22 12 36.4 0.95 6.4e-12 C6orf106 CRTAC1 CTD-3074O7.5 GALNT16 GRK4 KAT8 LINC00674 LMOD1 LOC100506990 LOC651250 MSRA NEAT1 PMS2P5 RBL2 RNF123 RP11-408A13.4 RP11-731C17.2 RP1-59D14.1 SIPA1 TEX15 TTC12 UHRF1BP1
Arm fat-free mass (left) 3.87 16 7 21.2 0.70 2.7e-03 C6orf106 CPO FNIP2 KAT8 LINC00674 LMOD1 LOC100506990 LOC651250 MARS2 MSRA NEAT1 PHLPP2 PROB1 RNF123 RP11-408A13.4 UHRF1BP1
Number of operations (self-reported) 2.55 2 0 0.0 0.00 1.0e+00 C6orf106 RNF123
Average weekly beer plus cider intake 2.70 1 1 3.0 0.00 1.0e+00 RNF123
Irritability 2.59 2 2 6.1 0.00 1.0e+00 LOC100506990 MSRA
Risk taking 2.02 1 0 0.0 0.00 1.0e+00 SDCCAG8
Diastolic blood pressure, automated reading 3.06 11 7 21.2 0.81 2.3e-03 AP000580.1 KAT8 LMOD1 LOC100506990 MSRA PBX3 PMS2P5 RNF123 SDCCAG8 SIPA1 TSNARE1
Unable to work because of sickness or disability 4.80 5 0 0.0 0.98 4.3e-03 GRK4 KAT8 LOXL1-AS1 RNF4 UHRF1BP1
Commuting to job workplace: Cycle 2.36 2 0 0.0 0.00 1.0e+00 RP1-59D14.1 TEX15
Myopia 2.13 1 0 0.0 0.00 1.0e+00 C6orf106
Vascular/heart problems diagnosed by doctor 3.69 12 5 15.2 -0.98 5.3e-08 CEP68 KAT8 LMOD1 LOC100506990 MSRA PMS2P5 RP11-375N15.2 RPS26 SDCCAG8 SIPA1 TEX15 TSNARE1
Cholesterol lowering medication 1.99 2 0 0.0 0.00 1.0e+00 CTD-3074O7.5 KAT8
Medication: Omeprazole (e.g. Zanprol) 2.05 1 0 0.0 0.00 1.0e+00 UHRF1BP1
Pain experienced in last month 5.02 9 2 6.1 -0.99 9.6e-07 CPO LINC00674 MAN1A2 PHLPP2 PPP6C RNF123 RP11-165J3.6 RP11-731C17.2 TMEM63C
Deep venous thrombosis (DVT) (self-reported) 1.09 1 0 0.0 0.00 1.0e+00 LOC100506990
Pack years of smoking 2.29 3 0 0.0 0.00 1.0e+00 GRK4 PMS2P5 RP1-59D14.1
Impedance of whole body 3.18 17 8 24.2 -0.84 2.1e-05 BTBD2 C6orf106 CPO FNIP2 KAT8 LMOD1 LOC100506990 MARS2 MSRA NEAT1 PMS2P5 RNF123 RP11-731C17.2 RP1-59D14.1 RPS26 STOML1 UHRF1BP1
Leg fat mass (left) 6.09 22 13 39.4 0.91 3.1e-09 BTBD2 C6orf106 CRTAC1 CTD-3074O7.5 GALNT16 GRK4 KAT8 LINC00674 LMOD1 LOC100506990 LOC651250 MSRA NEAT1 PMS2P5 RNF123 RP11-408A13.4 RP11-731C17.2 SIPA1 SNCA TEX15 TTC12 UHRF1BP1
Arm predicted mass (left) 3.92 16 7 21.2 0.69 2.9e-03 C6orf106 CPO FNIP2 KAT8 LINC00674 LMOD1 LOC100506990 LOC651250 MARS2 MSRA NEAT1 PHLPP2 PROB1 RNF123 RP11-408A13.4 UHRF1BP1

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 12 0.3437 2.24
GTEx Adipose Visceral Omentum 5 0.2456 2.22
GTEx Adrenal Gland 4 0.2745 2.08
GTEx Artery Aorta 7 0.2351 2.22
GTEx Artery Coronary 4 0.3381 2.21
GTEx Artery Tibial 9 0.2393 2.24
GTEx Brain Caudate basal ganglia 2 0.2174 2.24
GTEx Brain Cerebellar Hemisphere 6 0.4030 2.15
GTEx Brain Cerebellum 10 0.5045 2.30
GTEx Brain Cortex 6 0.5797 2.38
GTEx Brain Frontal Cortex BA9 4 0.4329 2.28
GTEx Brain Hippocampus 0 0.0000 1.91
GTEx Brain Hypothalamus 1 0.1695 1.91
GTEx Brain Nucleus accumbens basal ganglia 3 0.3468 2.02
GTEx Brain Putamen basal ganglia 1 0.1603 2.07
GTEx Breast Mammary Tissue 8 0.4053 2.27
GTEx Breast Mammary Tissue (Male) 1 0.0838 2.00
GTEx Breast Mammary Tissue (Female) 7 0.4258 2.16
GTEx Cells EBV-transformed lymphocytes 5 0.3514 2.36
GTEx Cells Transformed fibroblasts 15 0.3572 2.22
GTEx Colon Sigmoid 8 0.5472 2.31
GTEx Colon Transverse 6 0.2907 2.22
GTEx Esophagus Gastroesophageal Junction 10 0.6920 2.35
GTEx Esophagus Mucosa 9 0.2711 2.25
GTEx Esophagus Muscularis 17 0.5260 2.32
GTEx Heart Atrial Appendage 9 0.5700 2.25
GTEx Heart Left Ventricle 4 0.2614 2.12
GTEx Liver 3 0.4184 2.11
GTEx Lung 12 0.4177 2.28
GTEx Muscle Skeletal 4 0.1384 2.24
GTEx Nerve Tibial 10 0.2314 2.20
GTEx Ovary 3 0.3304 2.29
GTEx Pancreas 3 0.1838 2.14
GTEx Pituitary 3 0.2691 2.23
GTEx Prostate 4 0.4790 2.35
GTEx Skin Not Sun Exposed Suprapubic 12 0.4880 2.40
GTEx Skin Sun Exposed Lower leg 10 0.2747 2.32
GTEx Small Intestine Terminal Ileum 2 0.4338 2.42
GTEx Spleen 8 0.5670 2.39
GTEx Stomach 4 0.2751 2.26
GTEx Testis 7 0.2219 2.15
GTEx Thyroid 17 0.4251 2.25
GTEx Uterus 3 0.5291 2.18
GTEx Vagina 2 0.3150 2.27
GTEx Whole Blood 10 0.5018 2.23
METSIM Adipose 8 0.1735 2.03
NTR Blood 5 0.2082 2.09
ROSMAP Brain Pre-frontal Cortex 15 0.3416 2.22
YFS Blood 5 0.1083 1.97
CommonMind Brain Pre-frontal Cortex 13 0.2419 2.16
TCGA Breast Tumor 2 0.2608 2.14
TCGA Breast Normal 9 0.2139 1.90
TCGA Ovarian Tumor 3 0.1027 1.92
TCGA Prostate Tumor 7 0.2024 2.05